Influence of pharmaceutical funding on the conclusions of meta-analyses

British Medical Journal

Volumn 335, Issue 7631, 2007, Pages 1167-

  Epstein, Richard A ^a  

^a UNIVERSITY OF CHICAGO LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CLINICAL STUDY; DRUG INDUSTRY; EDITORIAL; FINANCIAL INFORMATION SYSTEM; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; MEDICAL EXPERT; MEDICOLEGAL ASPECT; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL;

DRUG INDUSTRY; META-ANALYSIS AS TOPIC; RESEARCH SUPPORT AS TOPIC;

EID: 37249083879     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39381.655845.BE     Document Type: Editorial

References (9)

1. Moynihan R. Who pays for pizza? Redefining the relationship between doctors and drug companies. BMJ 2003;326:1193-6.
2. Studdert DM, Mello MM, Brennan TA. Financial conflict of interest in physicians' relationships with the pharmaceutical industry - self-regulation in the shadow of federal prosecution. N Engl J Med 2004;351:1891-900.
3. Kassirer JP. On the take: how medicine's complicity with big business can endanger your health. New York: Oxford University Press, 2005.
4. Avom J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Random House, 2004.
5. Campbell EG, Gruen RL, Mountford J, Miller LG, Clearly PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007;356:1742-50.
6. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 2007;335:1202-5.
7. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health industry practices that create conflicts of interest, a policy proposal for American medical centers. JAMA 2006;295:429-33.
8. Stossel TP. Regulating academic-industrial research relationships - solving problems or stifling progress? N Engl J Med 2005;353:1060-5.
9. Epstein RA. Overdose: how excessive pharmaceutical regulation stifles pharmaceutical innovation. New Haven: Yale University Press, 2006.